Welcome to Cancer Gene Therapy

Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.

About the cover

Volume 24, No 5
May 2017

ISSN: 0929-1903
EISSN: 1476-5500

2015 Impact Factor 2.532*
58/124 Medicine, Research & Experimental
59/161 Biotechnology & Applied Micobiology
128/213 Oncology
82/165 Genetics & Heredity

Steven K. Libutti, M.D.

*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)


Open Access Funding
Visit the Cancer Gene Therapy open access funding page for information about research funders and institutions that provide funding for open access. Springer Nature also offers an article processing charge (APC) support service to make it easier for Cancer Gene Therapy authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.

For more information about Springer Nature's open access publishing options and policies, please see our open access homepage.

Extra navigation

24 May 2017